Efficacy of postoperative adjuvant therapy for invasive intraductal papillary mucinous carcinoma

DOI Web Site 25 References
  • HIRONO Seiko
    Division of Hepato-Biliary-Pancreatic Surgery, Department of Gastroenterological Surgery, Hyogo College of Medicine

Bibliographic Information

Other Title
  • Invasive IPMCに対する術後補助療法の有用性について

Search this article

Description

<p>An international consensus guideline for the management of patients with intraductal papillary mucinous neoplasm (IPMN) classified IPMNs pathologically into low-grade dysplasia, high-grade dysplasia, and invasive intraductal papillary mucinous carcinoma (IPMC). Once an IPMN has invasive components, lymph node metastases can occur and recurrence is often found even after complete surgical resection. In this event, the survival of patients with invasive IPMC is worse than that of patients with noninvasive IPMN. Therefore, lymphadenectomy during operation is essential for invasive IPMC to improve survival, similar to common pancreatic ductal adenocarcinoma. With regard to postoperative adjuvant therapy, some studies reported its effectiveness for patients with invasive IPMC to prolong the survival, while other studies did not. It is controversial whether adjuvant therapy should be administered to patients with invasive IPMC. This paper will introduce a project of the Japan Pancreas Society to evaluate the efficacy of postoperative adjuvant therapy for patients with invasive IPMC.</p>

Journal

  • Suizo

    Suizo 37 (4), 161-165, 2022-08-31

    Japan Pancreas Society

References(25)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top